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Purpose: To quantify gastrointestinal stromal tumor (GIST) patients’ preferences for reducing 
treatment toxicities and the likely effect of toxicities on patients’ stated adherence.
Methods: English-speaking members of the Life Raft Group, a GIST patient advocacy and 
research organization, aged 18 years and older, completed a web-enabled survey including a 
series of treatment-choice questions, each presenting a pair of hypothetical GIST medication 
toxicity profiles. Each profile was defined by common or concerning toxicities verified via pretest 
interviews including: severity of edema, diarrhea, nausea, fatigue, rash, hand-foot syndrome, and 
heart failure; and risk of serious infection. Each subject answered 13 choice-format questions 
based on a predetermined experimental design with known statistical properties. Subjects were 
asked to rate the likelihood that they would miss or skip doses of medications with different 
toxicity profiles. Random-parameters logit was used to estimate a relative preference weight 
for each level of toxicity.
Results: 173 subjects completed the survey. Over the ranges of toxicity levels included in 
the study, heart failure was the most important toxicity. Edema was the least important. For 
all toxicities, reducing severity from severe to moderate was more important to subjects than 
reducing severity from moderate to mild. Reducing heart failure from moderate to mild and 
diarrhea from severe to moderate had the largest effects on subjects’ evaluation of adherence.
Conclusions: All toxicities included in the study are important to patients. Treating or reducing 
severe toxicities is much more important to patients than treating or reducing moderate toxicities. 
Focused reductions of certain toxicities may improve treatment adherence.
Keywords: GIST, toxicities, patient preference, adherence, conjoint analysis, discrete choice 
experiment
Introduction
Gastrointestinal stromal tumors (GISTs) are a type of cancer that develops in the 
supportive or connective tissues of the digestive system. About 60% of GISTs occur in 
the stomach. GISTs are rare, with an annual incidence of 5,000 patients in the United 
States (US) (approximately 15 per million among adults). GISTs usually occur in people 
aged 50 years and older. Symptoms may include stomach pain, vomiting, bloody stools, 
fatigue, fever, and anemia. The exact causes of GISTs remain unknown, but research 
has indicated that tyrosine kinase inhibitors (TKIs) such as imatinib and sunitinib block 
the tyrosine kinase enzymes that GISTs need in order to grow. While imatinib remains 
the standard first-line therapy in metastatic GIST, a number of second-generation or 
broad-spectrum TKIs including nilotinib, sorafenib, and regorafenib are currently 
being investigated as second-, third-, or fourth-line treatments for those patients who Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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develop imatinib resistance.1 Imatinib,   sunitinib, and other 
targeted agents currently in development for treating GIST 
are associated with toxicities that are   difficult for some 
patients to tolerate.
For many patients these treatments have changed GIST 
from a fatal condition to a chronic disease requiring treatment 
for many years; thus, it is important to understand patients’ 
perceptions of these toxicities and the extent to which 
toxicities may affect adherence to treatment. The primary 
objectives of this research were to identify toxicities that are 
common and/or concerning for GIST patients and to elicit 
their preferences for avoiding toxicities associated with 
GIST treatments. A secondary objective was to estimate the 
potential impact of treatment-related toxicities on patients’ 
ratings of likely treatment adherence.
We identified common and concerning toxicities 
associated with GIST treatments. We then developed a 
choice-format conjoint-analysis survey to quantify the 
relative importance of different treatment toxicities to patients 
with GIST. Over the past decade, choice-format conjoint 
analysis – also known as discrete-choice experiment – has 
been used increasingly to quantify preferences for features 
of health, health care, and health care policy.2 Choice-
format conjoint analysis, as applied to health care decision 
making, is a systematic method of eliciting trade-offs to 
quantify the relative importance patients assign to various 
treatment outcomes. It is based on the premise that medical 
interventions are composed of a set of outcomes and that the 
attractiveness of a particular intervention to an individual is 
a function of these outcomes.3,4
In a choice-format conjoint-analysis survey of preferences 
for pharmaceutical treatments, treatment options are defined 
by a set of outcomes and each of those outcomes can take 
on different levels (eg, severity or risk). Outcome levels 
are combined into treatment profiles and the profiles are 
assembled into a number of choice pairs. Subjects are 
then asked to choose their preferred alternative between 
two treatment profiles in a series of choice questions. The 
resulting pattern of choices reveals the relative importance of 
each treatment outcome level and can be used to quantify the 
relative importance of changes in the level of an outcome.
Methods
survey sample
Study subjects were required to have a self-reported diagnosis 
of GIST and be aged 18 years or older. Subjects were 
recruited through the Life Raft Group (LRG), a GIST patient 
support and advocacy organization. LRG posted a link to 
the online survey on its website and sent an invitation to its 
members. All subjects were required to provide informed 
consent before completing the survey.
Sample-size calculations represent a challenge in   conjoint 
analysis. Minimum sample size depends on a number of 
criteria, including the question format, the complexity of 
the choice task, the desired precision of the results, and the 
need to conduct subgroup analyses.5 Researchers commonly 
apply a rule of thumb such as the algorithm proposed by 
Orme6 that suggests a minimum sample size as a function 
of the number of choice tasks, the number of alternatives per 
choice task, and the highest number of levels of any attribute 
in the study.6 Most published conjoint analysis studies have 
a sample size between 100 and 300 respondents.7 One recent 
conjoint-analysis study that used a choice-question format 
similar to the one used in this study included 153 subjects.8 
Therefore, the target minimum sample size for this study 
was 150 subjects.
survey instrument
Each subject was presented with a series of 13 treatment-
choice questions (Figure 1). In each treatment-choice 
question, subjects were asked to choose between two 
hypothetical GIST treatment profiles, each of which was 
defined by varying levels of eight treatment toxicities. 
Subjects were asked to assume that treatment efficacy was the 
same for all hypothetical treatment profiles included in the 
choice tasks. In addition, subjects were asked to assume 
that all medical bills, including the cost of medicines, 
were covered by health insurance. The survey instrument 
also elicited standard demographic information as well as a 
number of items about the patients’ experiences with GIST 
and GIST treatments.
The eight treatment toxicities were intended to represent 
toxicities that are common among GIST treatments and of 
concern to patients. These toxicities were identified based 
on a review of the published literature describing toxicities 
associated with current GIST treatments and consultation 
with clinical experts. Toxicities included edema, diarrhea, 
nausea, fatigue, skin rash, hand-foot syndrome, congestive 
heart failure, and serious infection with fever. For seven of 
the eight toxicities, toxicity levels were described as mild, 
moderate, or severe. For the eighth toxicity, serious infection 
with fever, the possible levels included 0% (None), 6%, 12%, 
and 25% chance of occurrence.
To estimate the potential impact of toxicities on adher-
ence, the survey also included adherence-rating questions. 
After each choice question, patients who indicated that Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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they miss or skip doses of their GIST medication at least 
  occasionally were asked to rate the relative likelihood that 
they would miss or skip doses of the hypothetical treatments 
in the choice question (Figure 1). This likelihood was rated 
on a 5-point Likert scale ranging from “Much more likely to 
miss or skip doses with Medicine A” to “Much more likely 
to miss or skip doses with Medicine B”. The middle level 
on the Likert scale was “Equally likely to miss or skip doses 
with Medicine A and Medicine B”.9,10
We conducted face-to-face, semistructured pretest 
interviews with a convenience sample of 5 subjects with a 
self-reported diagnosis of GIST who were referred by a practic-
ing, board-certified oncologist. The pretest subjects confirmed 
that the toxicities included in the survey instrument were 
both common and concerning and that no important toxicity 
was excluded. These pretest interviews also were used to test 
subjects’ comprehension of the survey instrument and the 
treatment-choice and adherence-rating questions. All 5 sub-
jects provided consistent feedback regarding the toxicities of 
interest and the understandability of the survey instrument.
To create treatment profiles for the choice questions, 
we employed a commonly used algorithm to construct an 
Figure 1 example of a trade-off question with adherence rating follow-up question.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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experimental design resulting in 48 choice pairs.11–15 The 
final experimental design consisted of four survey versions 
or blocks, each containing 12 choice pairs. Each subject was 
randomly assigned to one of the four blocks. All questions 
in a block were randomized for each subject. The survey 
was approved by RTI International’s Office of Research 
Protection and Ethics (Research Triangle Park, NC).
statistical analysis
We used multivariate, random-parameters regression to 
estimate a relative preference weight for each treatment 
toxicity level. In random-parameters logit, the independent 
variable is treatment choice and a regression equation is used 
to estimate the effect of each toxicity level on the probability 
of choosing a given treatment alternative. Each toxicity 
attribute was effects coded (eg, for a 3-level attribute: 0 1,   
1 0, -1 -1, such that the parameter for the omitted category 
is the negative sum of the included categories), rather than 
dummy coded (eg, 0 1, 1 0, 0 0) so that the mean effect for 
each outcome is normalized at zero instead of setting all the 
omitted categories to zero.16 Thus, the parameter estimate for 
each outcome level (toxicity severity or risk) is the log odds 
for that level. The log odds for each outcome level can be 
interpreted as the preference weight indicating the relative 
strength of preference for avoiding that toxicity level. For 
each toxicity, the difference between the highest and lowest 
preference weights represents the relative importance of 
avoiding that toxicity over the range of toxicity levels 
included in the survey.
Random-parameters logit avoids potential estimation 
bias from unobserved preference heterogeneity in discrete-
choice models by estimating a distribution of preferences 
across patients for each preference parameter.17,18 In addition, 
because each subject provided responses to more than one 
choice question, we estimated a random-effects panel model 
to account for within-subject correlation. Statistical analyses 
for the choice models were conducted using NLOGIT 4.0 
(Econometric Software, Inc, Plainview, NY).
The adherence-rating questions included in the survey 
asked patients to indicate how much more likely they 
would be to miss or skip doses of one treatment com-
pared to another. One possible response to this question is 
“Equally likely to miss or skip doses with Medicine A and 
Medicine B”. Choosing this response indicates that either 
the patient believes that he or she will not miss or skip 
doses with either treatment or that the outcomes of the two 
treatment profiles do not differ enough to induce a person 
to be less adherent with one treatment than with the other. 
In either case, choosing this response provides no information 
about the extent to which treatment attributes might affect 
  adherence. Therefore, we used a Heckman two-stage model 
to estimate first the effect of patient characteristics on the 
likelihood of choosing the response, “Equally likely to miss 
or skip doses with Medicine A and Medicine B” and then 
the effect of treatment toxicities on subjects’ assessment of 
the likelihood that he or she would miss or skip doses.9,10 
In the first stage, the dependent variable indicated whether 
a patient chose a response other than “Equally likely to miss 
or skip doses with Medicine A and Medicine B” and patient-
specific characteristics were used as explanatory variables. 
In the second stage of the adherence rating model, patients’ 
ratings of the likelihood of missing or skipping doses was 
modeled as a function of treatment toxicities. Specifically, 
we estimated an ordered-probit model in which the levels of 
the treatment attributes were used to predict the likelihood of 
choosing an adherence rating incorporating the results of the 
first stage by controlling for those who indicated that treat-
ment attributes would likely not affect treatment adherence. 
Statistical analyses for the adherence models were conducted 
using STATA 8.2 (Statacorp, College Station, TX).
Results
survey sample
One hundred and seventy-three members of LRG consented 
to participate and completed the survey during March 2010. 
The gender of the sample was distributed evenly between 
males and females (51% female). The majority of patients 
(93%) were white, and approximately 75% of patients were 
married. The mean age was 57 years (SD ± 12.8). Of the 
173 patients, 80% indicated that they currently take an oral 
medication to treat their GIST. The majority of subjects (66%) 
rated their GIST as currently under control with treatment. 
Nearly all subjects in the sample (99.4%)   indicated that they 
had previously experienced one or more of the   toxicities 
described in the survey. The most common toxicities reported 
were fatigue (81.5%), edema (68.2%), and diarrhea (64.7%). 
Table 1 presents the demographic characteristics of the 
sample. GIST and GIST treatment experience is summarized 
in Table 2. Patients’ self-reported assessment of adherence 
is presented in Table 3.
Twelve patients did not answer all of the choice questions. 
Only complete data was included in the analysis.
Preference weights
Figure 2 presents the preference weights for all toxicity 
levels. More-preferred outcomes have higher preference Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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weights than less-preferred outcomes. The estimated pref-
erence weights for all eight toxicities were consistent with 
the natural ordering of the categories where better clini-
cal outcomes were preferred to worse clinical outcomes. 
The vertical bars around each mean parameter estimate 
represent the 95% confidence interval. If the confidence 
intervals do not overlap for adjacent levels within a par-
ticular attribute, the mean estimates are significantly dif-
ferent from each other at the 5% level. For example, the 
preference weights for the levels of nausea severity are 
all significantly different indicating that mild nausea is 
significantly preferred to moderate nausea which, in turn, 
is significantly preferred to severe nausea. In contrast, the 
mean preference-weight estimates were ordered correctly 
for skin rash, but the statistical significance of the differ-
ence between the preference weight for mild and moderate 
Table 1 sample demographic characteristics
Characteristic Statistic or category Subjects  
N = 173
gender Male 84 (48.6%)
Female 89 (51.4%)
Age Mean (sD) 56.6 (12.8)
Marital status Married 129 
(74.6%)
Widowed 7 (4.0%)
Divorced or separated 14 (8.1%)
single 18 (10.4%)
Other 5 (2.9%)
racial or ethnic group White/caucasian 160 
(92.5%)
Asian 9 (5.2%)
Hispanic/latino 2 (1.2%)
native American 3 (1.7%)
country of residence United states 138 
(79.8%)
canada 9 (5.2%)
United Kingdom 9 (5.2%)
Australia 1 (0.6%)
Other 16 (9.2%)
education High school or secondary  
school certificate or  
equivalent
15 (8.7%)
4-year college or university  
degree (eg, BA, Bs, Bsc)  
or less, but more than high  
school or secondary school  
certificate or equivalent
87 (50.3%)
More than a 4-year  
college or university degree
71 (41.0%)
employment status employed 83 (48.0%)
Homemaker 7 (4.0%)
student 1 (0.6%)
retired 60 (34.7%)
Other 22 (12.7%)
Table 2 gisT treatment experience
Characteristic Statistic or category Subjects  
N = 173
current Health rating  
(0 = worst, 100 = best)
Mean (sD) 74.3 (20.6)
Time since diagnosis Less than 6 months ago 
At least 6 months ago,  
but less than 1 year ago 
At least 1 year, but  
less than 2 years ago 
At least 2 years, but  
less than 5 years ago 
At least 5 years ago
5 (2.9%) 
14 (8.1%) 
 
19 (11.0%) 
 
49 (28.3%) 
 
86 (49.7%)
Had surgery to  
treat gisT
Yes
no
151 (87.3%)
22 (12.7%)
currently taking medicine  
to treat gisT
Yes 139 (80.3%)
How do you receive  
your gisT medicine?
Pills 
Both pills and iV medicine
138 (99.3%) 
1 (0.7%)
experienced Toxicities Water retention and  
swelling 
Diarrhea 
nausea 
Feeling tired 
skin rash 
redness and sores  
on hands and feet 
Heart trouble 
Hospitalized from  
serious infection 
Missing
118 (68.2%) 
 
112 (64.7%) 
83 (48.0%) 
141 (81.5%) 
76 (43.9%) 
39 (22.5%) 
 
27 (15.6%) 
15 (8.7%) 
 
1 (0.06%)
Who do you turn to  
when you have toxicities  
from your gisT medicine?  
(Multiple responses were  
possible.)
My gisT doctor  
(a specialist) 
My regular doctor  
(primary care physician) 
A nurse 
A pharmacist 
Another specialist (such  
as a dermatologist) 
Other people with gisT 
Other 
none of the above
150 (86.7%) 
 
42 (24.3%) 
 
15 (8.7%) 
6 (3.5%) 
12 (6.9%) 
 
52 (30.1%) 
24 (13.9%) 
3 (1.7%)
Abbreviations: gisT, gastrointestinal stromal tumors; sD, standard deviation.
levels cannot be readily assessed by looking at the figure. In 
this case, preferences for avoiding mild and moderate skin 
rash are not statistically different at the 95% confidence 
level (P . 0.05).
The vertical distance between adjacent preference 
weights represents the relative importance of moving from 
one level of an attribute to an adjacent level of that toxicity. 
For example, the relative importance of an improvement 
in moderate nausea to mild nausea is approximately 0.7 
(approximately 0.4–1.1). Likewise, an improvement 
from severe skin rash to moderate skin rash has a relative 
importance of approximately 1.3 (approximately -0.9–0.4). Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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Therefore, an improvement from severe skin rash to moderate 
skin rash was approximately 1.9 (1.3/0.7) times as important   
to subjects as an improvement from moderate nausea to mild 
nausea. Over the range of levels of each toxicity in the study, 
congestive heart failure was the most important toxicity. The 
remaining toxicities were ranked in order of importance as 
follows: serious infection, nausea, diarrhea, hand-foot syn-
drome, fatigue, skin rash, and edema.
Adherence ratings
The first stage of the adherence rating model indicated that 
patients who discuss treatment toxicities with other GIST 
patients and patients who had had prior surgery to treat 
GIST were more likely to choose something other than 
“Equally likely to miss or skip doses with Medicine A and 
Medicine B”. In contrast, married patients and patients who 
discussed treatment toxicities with a pharmacist or specialist 
were less likely to indicate that treatment toxicities will affect 
the likelihood of missing or skipping doses than patients 
without prior treatment experience. We found no effect of 
employment on the likelihood that a patient would miss or 
skip doses. In the second stage of the model, all toxicities had 
an impact on the likelihood of missing or skipping doses. The 
effect of each toxicity level on likely adherence is presented 
in Figure 3. Reducing the severity of congestive heart failure 
from moderate to mild and reducing the severity of diarrhea 
from severe to moderate had the largest effect on likely 
adherence. Reducing the likelihood of serious infection from 
12% to 6% had the third largest effect on likely adherence. 
In contrast, reducing the severity of edema from moderate to 
mild had the smallest effect on likely adherence.
Discussion
The primary objectives of this research were to identify 
toxicities that are common and/or of concern to people with 
GIST and to elicit patient preferences for avoiding toxicities 
associated with GIST treatments. All toxicities included in 
the survey are important to patients with GIST. Treating or 
reducing the severity of toxicities from severe to moderate 
generally was more important to subjects than reducing 
severity from moderate to mild. This preference implies 
that treating or reducing severe toxicities was much more 
important to subjects than treating or reducing moderate 
toxicities.
A secondary objective was to estimate the potential 
impact of treatment-related toxicities on patients’ ratings 
of likely treatment adherence. For subjects who reported 
missing or skipping treatment doses in the past, toxicities 
included in the survey were rated as being likely to affect 
adherence. Congestive heart failure, serious infection and 
fever, and diarrhea were the toxicities rated as being most 
likely to affect adherence. Because the sample size in this 
Table 3 gisT treatment adherence experience
Characteristic Statistic or category Subjects  
N = 173
About how often would you say you miss or  
skip a dose of your gisT medicine?
never 
Less than once per month 
Between 2 and 5 times per month 
More than 5 times per month 
Missing
92 (53.2%) 
51 (29.5%) 
21 (12.1%) 
6 (3.5%) 
3 (1.7%)
Which of the following statements describes the  
reasons you might miss or skip doses of your  
gisT medicines? (check all that apply.)
n 
i sometimes stop taking my gisT medicine when i am sick with  
another illness such as a stomach illness or the flu. 
I take a lot of medicines every day, and it can be difficult to keep  
track of them. 
i sometimes forget to take my medicines because i am busy working,  
taking care of children, or participating in other activities. 
i do not take my gisT medicine when i have things to do (such as traveling  
or working) so that the toxicities will not interfere with these activities. 
i sometimes don’t think the medicine is working well, so it isn’t worth taking. 
i sometimes don’t like the toxicities of my medicine and take it less  
often to avoid or reduce these toxicities. 
i stop taking the medicine sometimes because i am having toxicities and  
my doctor tells me to stop the medicine until the toxicities go away. 
I sometimes find it difficult to pay for my medicines and wait to  
refill my prescriptions until I have the money.
78 
24 (30.8%) 
 
6 (7.7%) 
 
36 (46.2%) 
 
15 (19.2%) 
 
3 (3.8%) 
14 (17.9%) 
 
17 (21.8%) 
 
2 (2.6%)
Abbreviation: gisT, gastrointestinal stromal tumors.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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study was chosen to estimate preference weights and not 
adherence weights and because a large majority of subjects 
reported not being willing to miss or skip treatment doses 
under any circumstance, the adherence weights presented in 
this study have very large confidence intervals. Therefore, the 
adherence results presented in this study should be viewed 
with caution. Further study will be required to determine 
whether toxicities are likely to have a statistically significant 
effect on subjects’ rating of likely adherence.
While choice-format conjoint analysis methods are widely 
used in health economics to elicit preferences for treatment 
features and outcomes, they have limitations. One inherent 
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limitation is that subjects evaluate hypothetical treatments. 
These constructed choice questions are intended to simulate 
possible clinical decisions but do not have the same clinical, 
financial, and emotional consequences as actual decisions. 
Thus, differences can arise between stated and actual choices. 
We have attempted to minimize such potential differences 
by offering alternatives that mimic real-world trade-offs as 
closely as possible. In addition, some health professionals 
are skeptical that people have sufficient understanding of 
treatment information to competently evaluate treatment 
alternatives. Diagnosis among subjects in this study was 
self-reported and not confirmed by physician consultation 
or chart review. However, we believe it unlikely that people 
without GIST would complete this type of study because the 
study is cognitively challenging and requires an investment 
in time, in exchange for little personal gain.
Subjects in this study were recruited through a patient 
support and advocacy organization. These subjects appear 
more highly educated than the general population and the 
majority were diagnosed with GIST at least 5 years prior to 
completing the survey. Therefore, the results of this study 
likely are not generalizable to all GIST patients, but reflect 
the preference of patients who are experienced and active in 
the treatment of the disease.
Conclusion
This study demonstrates that people with GIST have clear 
and measurable preferences for reducing toxicities associated 
with GIST treatments. Discussing treatment toxicities with 
patients and treating those toxicities that are most important 
to patients may enable physicians and other health care pro-
fessionals to reduce the effect that treatment toxicities have 
on patients’ quality of life. The adherence results presented 
in this study suggest that treatment toxicities may affect treat-
ment adherence. Understanding the extent to which toxicities 
may affect adherence can help health care professionals man-
age GIST treatments and improve treatment adherence.
Disclosure
This study was funded by Novartis Pharmaceuticals 
Corporation, NJ, USA.
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